SEARCH

SEARCH BY CITATION

References

  • 1
    Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 2000; 60: 68647.
  • 2
    Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 7047.
  • 3
    Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. New Eng J Med 1995; 33: 9757.
  • 4
    Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 12606.
  • 5
    Schneider-Stock R, Giers A, Motsch C, Boltze C, Evert M, Freigang B, Roessner A. Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. (Letter) Am J Hum Genet 2003; 72: 21618.
  • 6
    Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 118916.
  • 7
    Smigiel R, Sasiadek M, Krecicki T, Ramsey D, Jagielski J, Blin Śmigieł. Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx. Mol Carcinog 2004; 39: 14754.
  • 8
    Debniak T, Gorski B, Scott RJ, Cybulski C, Medrek K, Zlowocka E, Kurzawski G, Debniak B, Kladny J, Bielecka-Grzela S, Maleszka R, Lubinski J. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer 2004; 110: 55862.
  • 9
    Lamperska K, Karezewska A, Kwiatkowska E, Mackiewicz A. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol 2002; 49: 36976.
  • 10
    Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 1995; 10: 1146.
  • 11
    Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 1996; 66: 24954.
  • 12
    Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999; 9: 44652.
  • 13
    Dębniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Dębniak B, Załuga E, Maleszka R, Kładny J, Górski B, Cybulski C, Gronwald J, et al. The CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005; 65: 8359.
  • 14
    Dębniak T, Górski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, Grzybowska E, Stawicka M, et al. A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 2005; 42: 7635.
  • 15
    Ott J. Utility programs for analyisis of genetic linkage; Program HWE, URL: http://www.hgmp.mrc.ac.uk/Registered/Help/linkutil/, 1988.
  • 16
    Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110: 6836.
  • 17
    Cybulski C, Huzarski T, Gorski B, Masojc B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Zlowocka E, Kurzawski G, Sikorski A, Posmyk M, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004; 64: 26779.
  • 18
    Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, Chaubert P. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 2001; 81: 21729.
  • 19
    Mantelli M, Barile M, Ciotti P, Ghiorzo P, Lantieri F, Pastorino L, Catricala C, Torre GD, Folco U, Grammatico P, Padovani L, Pasini B, et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 2002; 107: 21421.
  • 20
    Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BA, Mann GJ, Bishop DT, Newton BJ. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 2000; 28: 4557.